Syndax Pharmaceuticals Inc buy tamam
Start price
18.01.18
/
50%
€8.25
Target price
04.11.21
€28.00
Performance (%)
74.48%
End price
05.11.21
€14.40
Summary
This prediction ended on 05.11.21 with a price of €14.40. With a performance of 74.48% the BUY prediction by tamam was a big success. tamam has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Syndax Pharmaceuticals Inc | -13.462% | -13.462% | -4.255% | 50.000% |
| iShares Core DAX® | -5.744% | -6.037% | 9.155% | 8.257% |
| iShares Nasdaq 100 | -4.907% | -12.083% | 19.607% | 30.219% |
| iShares Nikkei 225® | -7.230% | -10.182% | 3.445% | -1.121% |
| iShares S&P 500 | -4.764% | -6.545% | 19.194% | 31.957% |
Comments by tamam for this prediction
In the thread Syndax Pharmaceuticals Inc diskutieren
Syndax as an Out the Gate 2018 Pick
... due to the highly favorable risk/reward dynamics in the Phase III E2112 trial, with interim data expected in 2Q18, plus additional potential for Syndax in Phase II studies in combination with immune checkpoint drugs in various solid cancers, particularly PD-1 refractory melanoma.
tamam stimmt am 18.01.2018 der Buy-Einschätzung der institutionellen Analysten mit dem Kursziel 27,25$ zu.
Kursziel geändert auf 16,0
Kursziel geändert auf 18,0
Kursziel geändert auf 28,0
In the thread Trading Syndax Pharmaceuticals Inc
Die von tamam gewählte maximale Laufzeit wurde überschritten